← 홈

ADC · 폐암 (NSCLC)

4개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4개
ADCABiologicstaleJanssen Research & Development,…Phase 3

Osimertinib (Osimertinib)

Carcinoma, Non-Small-Cell Lung · FRα

#FR#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 76.7%임상시험 88상태 RECRUITING
ADCCBiologicstaleNovartis PharmaceuticalsdeliveryPhase 3

Trametinib (Trametinib)

KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 100%임상시험 79상태 DISCONTINUED
ADCBiologicstaleSWOG Cancer Research NetworksPhase 3

Afatinib Dimaleate (Afatinib Dimaleate)

Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 96%임상시험 59상태 RECRUITING
ADCBiologicstalePfizerderuxtecan showed encouragi…Phase 1

Dacomitinib (Dacomitinib)

Non-Small Cell Lung Cancer · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 75.3%임상시험 46상태 DISCONTINUED